KVUE Stock Recent News
KVUE LATEST HEADLINES
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue shares progress on its Environmental, Social and Governance goals in its first-ever Healthy Lives Mission Report.
Kenvue (KVUE) was created as the result of a spinoff from Johnson & Johnson and encompasses the consumer side of the business. KVUE manages a wide array of products within each segment, but sales volume remains vulnerable to consumer spending. Data shows us that consumers are willing to go with store-branded generics as an alternative to name brands under KVUE's umbrella to save money.
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue will participate in Deutsche Bank's dbAccess Global Consumer Conference in Paris, France.
Too often spinoff stocks don't perform well out of the gate. Because an investor bought the business of the parent company, he doesn't care too much about whatever side project is being shed.
Kenvue (NYSE: KVUE ) stock is in the news Monday after the company announced that Johnson & Johnson (NYSE: JNJ ) is selling its stake in the business. Kenvue has announced a secondary offering that will have Johnson & Johnson selling its entire stake of 182,329,550 shares of KVUE stock.
Kenvue Inc.'s stock fell 1.8% early Monday, after the consumer-health business, which was spun out of Johnson & Johnson last year, announced plans for a secondary offering of 182.3 million shares.
Kenvue beat Wall Street estimates for first-quarter profit on Tuesday, and said it would cut 4% of its global workforce amid the Tylenol and Band-Aid maker's efforts to expand its key brands.
An Illinois court late Friday ordered pharmaceutical giant Johnson & Johnson and Kenvue to pay $45 million to a family that alleged the companies' talcum-based baby powder led to the death of a relative diagnosed with a fatal cancer linked to asbestos exposure, the company's latest legal issue involving talc products.
Kenvue (KVUE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Alex Fitch, Harris Associates director of U.S. Research, joins 'Money Movers' to discuss Fitch's investment thesis towards Delta Air Lines, whether investors are not supposed to buy cyclical stocks at peak earnings, and more.